The affected lots, No. 6120341 and No. 6120420, were distributed between Dec. 6, 2018, and Feb. 20, 2019.
“Products containing glass particulate should not be administered intravenously due to the potential for life-threatening consequences,” the drugmaker said in its recall notice.
To date, Fresenius said it hasn’t received reports of adverse events related to the glass particles.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
